Welcome to the 62nd annual meeting of the American Society of Hematology. This year’s
congress is unique among ASH annual meetings—the first to be all-virtual and the first to be
held in the midst of a raging pandemic.
And just as the annual meeting has had to adapt to the circumstances, so too has
Hematology 2020. For the first time, this year’s edition is electronic-only. Some of the chapters
reference COVID-19 and its impact on hematologic disorders. Other new features include
a new page design, visual abstracts, and shorter manuscripts with the aim of making
Hematology more graphical.
In spite of these changes, the essence of Hematology remains the same. As always, you
can count on high quality content spanning the breadth of malignant and nonmalignant
hematology, based on a state-of-the-art Education Program prepared by this year’s Education
Co-Chairs, Dr. Sioban Keel and Dr. Christopher Flowers. Dr. Andrew Roberts will
deliver the Ham-Wasserman Lecture on Therapeutic Development and Current Uses of
BCL-2 Inhibition, and his article is also included.
This volume is the culmination of the efforts of many individuals and their selfless commitment
to ASH, including the authors, reviewers, designer (Debra Naylor), and ASH staff
(Michelle Lee, Kenneth April, and Brian Cannon).
In these difficult times, we hope that you find Hematology to be the valued resource that it
has always strived to be: a means of helping you keep current with the torrid pace of progress
in hematology by highlighting recent practice-changing clinical advances as well as putting
cutting edge basic advances into clinical context. Happy reading, and please stay safe.
Author(s): Adam Cuker, Mario Cazzola, Stella T. Chou, Ann LaCasce, David Garcia
Series: Hematology, the ASH Education Program
Publisher: American Society of Hematology
Year: 2020
Language: English
Tags: Hematology; American Society of Hematology; ASH Education Program; Blood Diseases
Front Cover
Contents
Editors’ Message
Reviewers
Continuing Medical Education Information
Ham-Wasserman Lecture
Therapeutic development and current uses of BCL-2 inhibition
A Map for the Changing Landscape of CLL
Approaches for relapsed CLL after chemotherapy-free frontline regimens
Chemotherapy-free frontline therapy for CLL:is it worth it?
Standard treatment approaches for relapsed/refractory CLL after frontline chemoimmunotherapy
Treatment of relapsed CLL after venetoclax
Acute Myeloid Leukemia—So Many Treatment Options; How Do You Decide?
Does patient fitness play a role in determining first-line treatment of AML?
How to approach shared decision making when determining consolidation, maintenance therapy,and transplantation in AML
Management of toxicities associated with targeted therapies for AML: when to pushthrough and when to stop
Advances in the Laboratory Assessment of Hemostatic and Thrombotic Disorders
“TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry
Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, andplatelet disorders
Laboratory surveillance of immune-mediated TTP
Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
Can we use epigenetics to prime chemoresistant lymphomas?
Harnessing lymphoma epigenetics to improve therapies
Novel targets in aggressive lymphoma
Beyond the Marrow
Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes
Extrahematopoietic manifestations of the short telomere syndromes
Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer?
Optimizing management of acute leukemia in community centers and when to refer
Practice patterns and outcomes for adults with AML receiving care in community vs academic settings
AML—So Many Treatment Options; How Do You Decide?
Approaches to aggressive B-cell lymphomas in less fit patients
Challenging Situations for Patients with Aggressive Lymphomas
Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas
Strategies for aggressive T-cell lymphoma: divide and conquer
Chronic Transfusion Support: Challenging Cases
Challenges in chronic transfusion for patients with thalassemia
Outpatient transfusions for MDS
Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life
Diagnostic and Prognostic Models in VTE Management: Ready for Prime Time?
Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism?
When I treat a patient with acute pulmonary embolism at home
Which patients are at high risk of recurrent venous thromboembolism (DVT and PE)?
Advanced therapies and extracorporealmembrane oxygenation for the management of high-risk pulmonary embolism
Genetic Testing for Heritable Hematologic Disorders
Informed consent for genetic testingin hematology
Identifying potential germline variants from sequencing hematopoietic malignancies
Handling Challenging Questions in the Management of CML
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase CML?
How to manage CML patients with comorbidities
Handling challenging questions in themanagement of CML:when is it safe to stop tyrosine kinase inhibitors?
Immunotherapy in Multiple Myeloma
Sequencing multiple myeloma therapies with and after antibody therapies
Bispecifics, trispecifics, and other novel immune treatments in myeloma
Future of CAR T cells in multiple myeloma
Should all newly diagnosed MM patients receive CD38 antibody–based treatment?
Improving Symptom Control for Children with Hematological Malignancies
Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies
Indolent Lymphomas: Answers to Smoldering Questions
How do I sequence therapy for follicular lymphoma?
How do we sequence therapy for marginal zone lymphomas?
Transformed lymphoma: what should I do now?
Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases
Preventing infections in children and adults with asplenia
Managing Toxicities of Targeted Therapies in CLL
Managing toxicities of Bruton tyrosine kinase inhibitors
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of CLL
Management of AL amyloidosis in 2020
Monoclonal Gammopathies of Determined Significance
Management of Waldenstr¨om macroglobulinemia in 2020
Monoclonal gammopathies of clinical significance
More Anxiety-Provoking Hematology Consults
A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact
Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease
Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP
Myelodysplastic Syndromes: What We Have and What We Want
Existing agents, novel agents, or transplantation for high-risk MDS
Patient stratification in MDS: how a puzzle may become a map
Therapy for lower-risk MDS
Myeloproliferative Disorders: Too Many Cells, Too Few Therapies
Applied genomics in MPN presentation
Genomics of MPN progression
Genomics of MDS/MPN overlap syndromes
MDS/MPN overlap syndromes: a focused review
Out of Balance: Anemias Due to Disordered Iron Homeostasis
Inherited microcytic anemias
Global look at nutritional and functional iron deficiency in infancy
Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?
Pediatric Hematological Malignancies: CARs for Kids
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma
CAR T cells for other pediatric non–B-cell hematologic malignancies
CAR T cells vs allogeneic HSCT for poor-risk ALL
What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell ALL?
Platelet Transfusions for Hematology/Oncology Patients
Does ABO and RhD matching matter for platelettransfusion?
How well do platelets prevent bleeding?
Platelet transfusion refractoriness: how do I diagnose and manage?
The use of premedications for platelet transfusions in pediatric patients
Selected Hemostasis and Thrombosis Topics in Women
Management of heavy menstrual bleeding on anticoagulation
Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management
Women and bleeding disorders: diagnostic challenges
Abnormal uterine bleeding in users of rivaroxaban and apixaban
The Brain and Pain in Sickle Cell Disease
Neuropathic pain in sickle cell disease: measurement and management
Optimizing the management of chronic pain in sickle cell disease
The Emerging Role of Targeted Therapies and Cell Therapy in Transplant
Next-generation cell therapies: theemergingrole of CAR-NK cells
Practical aspects of building a new immunotherapy program: the future of cell therapy
Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma
Fundamentals of immunology for understanding immunotherapy for lymphoma
Immunotherapy with cells
Immunotherapy with drugs
Nonanticoagulant Interventions in Venous Thromboembolism
Role of venous stenting for venous thromboembolism
Thrombolytic therapy in acute venous thromboembolism
Inferior vena cava filters: a framework for evidence-based use
Do prophylactic inferior vena cava filters in trauma patients reduce the risk of mortality or pulmonary embolism?
What Hematologists Need to Know About Giving and Stopping Aspirin
Does aspirin prevent venous thromboembolism?
Combining antiplatelet and anticoagulant therapy in cardiovascular disease
Yin and Yang of Autoimmunity and Immunodeficiencies in Hematology
Allogeneic HSCT in adults with primary immunodeficiency
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)
Erratum
Blank Page
